Poland· PL-100525950
Vyvgart
A efgartigimod alfa product containing efgartigimod alfa, registered in Poland by argenx BV. The same ATC class is registered in 4 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Efgartigimod alfa is registered in 4 of 19 countries.
Countries holding a registration under ATC L04AA58 (efgartigimod alfa), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 2 of them publish a price we can compare per daily dose
Efgartigimod alfa · ATC L04AA58
4 / 19 countries
- Belgiumprice
- Canada
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Efgartigimod alfa
- Manufacturer
- argenx BV
- Country
- Poland (PL)
- ATC code
- L04AA58
- ATC class
- Efgartigimod alfa
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin04150197302503
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Efgartigimod alfa in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVYVGARTargenx BV, Gent
- SwedenVyvgart 1000 mg Injektionsvätska, lösningArgenx
- BelgiumVyvgart 1000 mgArgenx
- IcelandVyvgartArgenx BV
- SwitzerlandVyvgart 1000 mg/ 5 ml, solution injectable en seringue préremplieargenx Switzerland SA
- FranceVYVGART 1 000 mg, solution injectable en seringue préremplieARGENX (BELGIQUE)
- SpainVYVGART 1.000 MG SOLUCION INYECTABLEArgenx B.V.
- FinlandVyvgartArgenx
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vyvgart
- Liechtenstein · Vyvgart
- Norway · Vyvgart
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2df21be7-2ae1-4962-a5df-a4d4db1ebbec GET /v1/drugs/2df21be7-2ae1-4962-a5df-a4d4db1ebbec?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "1000 mg",
"packaging": "Rpz ¦ EU/1/22/1674/003 ¦ 163988\n1 amp.-strzyk. 5 ml\n¦ UR/Z/4b/248/25 - 04150197302503 ¦ UR/Z/4b/261/25 - 04150197302503\nRpz ¦ EU/1/22/1674/004 ¦ 163990\n4 amp.-strzyk. 5 ml",
"substance": "Efgartigimod alfa 1000 mg",
"common_name": "Efgartigimod alfa",
"pl_product_id": "100525950",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about efgartigimod alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.